Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452-8

Eur Urol. 2019 Oct;76(4):e109-e110. doi: 10.1016/j.eururo.2019.04.041. Epub 2019 May 10.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Ataxia Telangiectasia Mutated Proteins / genetics
  • BRCA1 Protein / genetics
  • BRCA2 Protein
  • Humans
  • Male
  • Mutation
  • Phthalazines
  • Piperazines
  • Prostatic Neoplasms, Castration-Resistant*

Substances

  • BRCA1 Protein
  • BRCA1 protein, human
  • BRCA2 Protein
  • BRCA2 protein, human
  • Phthalazines
  • Piperazines
  • ATM protein, human
  • Ataxia Telangiectasia Mutated Proteins
  • olaparib